Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3947041rdf:typepubmed:Citationlld:pubmed
pubmed-article:3947041lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:3947041lifeskim:mentionsumls-concept:C1096063lld:lifeskim
pubmed-article:3947041lifeskim:mentionsumls-concept:C0003286lld:lifeskim
pubmed-article:3947041lifeskim:mentionsumls-concept:C0205171lld:lifeskim
pubmed-article:3947041lifeskim:mentionsumls-concept:C1523987lld:lifeskim
pubmed-article:3947041pubmed:issue1lld:pubmed
pubmed-article:3947041pubmed:dateCreated1986-3-11lld:pubmed
pubmed-article:3947041pubmed:abstractTextFifty-nine patients with chronic generalized tonic-clonic or partial seizures refractory to the maximally tolerated daily dosage of single-drug therapy with carbamazepine, phenytoin, phenobarbital, or primidone subsequently received single-drug therapy with another one of these primary anticonvulsant drugs. Alternative single-drug therapy resulted in complete seizure control or more than 75% seizure reduction for 18 patients (31%). Side effects disappeared in 16 patients (27%). Patients with a good therapeutic response often had epilepsy of recent onset. Alternative single-drug therapy is beneficial for chronic refractory epilepsy and should be considered before a second drug is permanently added.lld:pubmed
pubmed-article:3947041pubmed:languageenglld:pubmed
pubmed-article:3947041pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3947041pubmed:citationSubsetIMlld:pubmed
pubmed-article:3947041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3947041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3947041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3947041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3947041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3947041pubmed:statusMEDLINElld:pubmed
pubmed-article:3947041pubmed:monthJanlld:pubmed
pubmed-article:3947041pubmed:issn0364-5134lld:pubmed
pubmed-article:3947041pubmed:authorpubmed-author:SchmidtDDlld:pubmed
pubmed-article:3947041pubmed:authorpubmed-author:RichterKKlld:pubmed
pubmed-article:3947041pubmed:issnTypePrintlld:pubmed
pubmed-article:3947041pubmed:volume19lld:pubmed
pubmed-article:3947041pubmed:ownerNLMlld:pubmed
pubmed-article:3947041pubmed:authorsCompleteYlld:pubmed
pubmed-article:3947041pubmed:pagination85-7lld:pubmed
pubmed-article:3947041pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3947041pubmed:meshHeadingpubmed-meshheading:3947041-...lld:pubmed
pubmed-article:3947041pubmed:meshHeadingpubmed-meshheading:3947041-...lld:pubmed
pubmed-article:3947041pubmed:meshHeadingpubmed-meshheading:3947041-...lld:pubmed
pubmed-article:3947041pubmed:meshHeadingpubmed-meshheading:3947041-...lld:pubmed
pubmed-article:3947041pubmed:meshHeadingpubmed-meshheading:3947041-...lld:pubmed
pubmed-article:3947041pubmed:meshHeadingpubmed-meshheading:3947041-...lld:pubmed
pubmed-article:3947041pubmed:meshHeadingpubmed-meshheading:3947041-...lld:pubmed
pubmed-article:3947041pubmed:meshHeadingpubmed-meshheading:3947041-...lld:pubmed
pubmed-article:3947041pubmed:meshHeadingpubmed-meshheading:3947041-...lld:pubmed
pubmed-article:3947041pubmed:year1986lld:pubmed
pubmed-article:3947041pubmed:articleTitleAlternative single anticonvulsant drug therapy for refractory epilepsy.lld:pubmed
pubmed-article:3947041pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3947041pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3947041lld:pubmed